I think DXB is suffering from over promising and under...

I think DXB is suffering from over promising and under delivering. Nina was everywhere a few months ago telling us that an agreement was “imminent” and that multiple parties were doing due diligence. Then - nothing.
The market hates delays and there is clearly delays within the DXB process. With other bios running and many stocks pushing to new highs the opportunity cost of holding this is getting too high for many punters.
If there is news flow and if patient sign up is confirmed and if the r&d rebate comes in and IF an agreement is signed then investors will come back. Until then it will continue to drift lower as there are much better options out there.